Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

BACKGROUND: Randomized clinical trials in non-critically ill COVID-19 patients showed that therapeutic-dose heparin increased survival with reduced organ support as compared with usual-care thromboprophylaxis, albeit with increased bleeding risk. The purpose of the study is to assess the safety of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosmi, B., Giannella, M., Fornaro, G., Cristini, F., Patacca, A., Castagna, A., Mazzaferri, F., Testa, S., Pan, A., Lupi, M., Brambilla, P., Montineri, A., Frattima, S., Bignami, E. G., Salvetti, M., De Stefano, G., Grandone, E., Di Perri, G., Rozzini, R., Stella, A., Romagnoli, A., Drago, F., Viale, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594805/
https://www.ncbi.nlm.nih.gov/pubmed/37875792
http://dx.doi.org/10.1186/s12879-023-08297-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594805/
https://www.ncbi.nlm.nih.gov/pubmed/37875792
http://dx.doi.org/10.1186/s12879-023-08297-7

Ejemplares similares